Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsx
<p>Inflammatory Bowel Disease (IBD), which includes Ulcerative Colitis (UC) and Crohn’s Disease (CD), is marked by dysbiosis of the gut microbiome. Despite therapeutic interventions with biological agents like Vedolizumab, Ustekinumab, and anti-TNF agents, the variability in clinical, histolog...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852023197033037824 |
|---|---|
| author | Federico Melograna (12202905) |
| author2 | Padhmanand Sudhakar (6505280) Behnam Yousefi (15467168) Clara Caenepeel (20632751) Gwen Falony (2608516) Sara Vieira-Silva (185473) Sreenikhitha Krishnamoorthy (20632754) David Fardo (6105143) Bram Verstockt (6095060) Jeroen Raes (6041) Severine Vermeire (5649814) Kristel Van Steen (189124) |
| author2_role | author author author author author author author author author author author |
| author_facet | Federico Melograna (12202905) Padhmanand Sudhakar (6505280) Behnam Yousefi (15467168) Clara Caenepeel (20632751) Gwen Falony (2608516) Sara Vieira-Silva (185473) Sreenikhitha Krishnamoorthy (20632754) David Fardo (6105143) Bram Verstockt (6095060) Jeroen Raes (6041) Severine Vermeire (5649814) Kristel Van Steen (189124) |
| author_role | author |
| dc.creator.none.fl_str_mv | Federico Melograna (12202905) Padhmanand Sudhakar (6505280) Behnam Yousefi (15467168) Clara Caenepeel (20632751) Gwen Falony (2608516) Sara Vieira-Silva (185473) Sreenikhitha Krishnamoorthy (20632754) David Fardo (6105143) Bram Verstockt (6095060) Jeroen Raes (6041) Severine Vermeire (5649814) Kristel Van Steen (189124) |
| dc.date.none.fl_str_mv | 2025-01-29T05:19:52Z |
| dc.identifier.none.fl_str_mv | 10.3389/fmolb.2024.1490533.s003 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_3_Individual-network_based_predictions_of_microbial_interaction_signatures_for_response_to_biological_therapies_in_IBD_patients_xlsx/28301414 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Molecular Biology inflammatory bowel disease therapy fecal microbiota 16S profiling individual specific networks response prediction |
| dc.title.none.fl_str_mv | Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsx |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Inflammatory Bowel Disease (IBD), which includes Ulcerative Colitis (UC) and Crohn’s Disease (CD), is marked by dysbiosis of the gut microbiome. Despite therapeutic interventions with biological agents like Vedolizumab, Ustekinumab, and anti-TNF agents, the variability in clinical, histological, and molecular responses remains significant due to inter-individual and inter-population differences. This study introduces a novel approach using Individual Specific Networks (ISNs) derived from faecal microbial measurements of IBD patients across multiple cohorts. These ISNs, constructed from baseline and follow-up data post-treatment, successfully predict therapeutic outcomes based on endoscopic remission criteria. Our analysis revealed that ISNs characterised by core gut microbial families, including Lachnospiraceae and Ruminococcaceae, are predictive of treatment responses. We identified significant changes in abundance levels of specific bacterial genera in response to treatment, confirming the robustness of ISNs in capturing both linear and non-linear microbiota signals. Utilising network topological metrics, we further validated these findings, demonstrating that critical microbial features identified through ISNs can differentiate responders from non-responders with respect to various therapeutic outcomes. The study highlights the potential of ISNs to provide individualised insights into microbiota-driven therapeutic responses, emphasising the need for larger cohort studies to enhance the accuracy of molecular biomarkers. This innovative methodology paves the way for more personalised and effective treatment strategies in managing IBD.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_9ea4e41e80f790cb5e816d971ea825bf |
| identifier_str_mv | 10.3389/fmolb.2024.1490533.s003 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/28301414 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsxFederico Melograna (12202905)Padhmanand Sudhakar (6505280)Behnam Yousefi (15467168)Clara Caenepeel (20632751)Gwen Falony (2608516)Sara Vieira-Silva (185473)Sreenikhitha Krishnamoorthy (20632754)David Fardo (6105143)Bram Verstockt (6095060)Jeroen Raes (6041)Severine Vermeire (5649814)Kristel Van Steen (189124)Molecular Biologyinflammatory bowel diseasetherapyfecal microbiota16S profilingindividual specific networksresponse prediction<p>Inflammatory Bowel Disease (IBD), which includes Ulcerative Colitis (UC) and Crohn’s Disease (CD), is marked by dysbiosis of the gut microbiome. Despite therapeutic interventions with biological agents like Vedolizumab, Ustekinumab, and anti-TNF agents, the variability in clinical, histological, and molecular responses remains significant due to inter-individual and inter-population differences. This study introduces a novel approach using Individual Specific Networks (ISNs) derived from faecal microbial measurements of IBD patients across multiple cohorts. These ISNs, constructed from baseline and follow-up data post-treatment, successfully predict therapeutic outcomes based on endoscopic remission criteria. Our analysis revealed that ISNs characterised by core gut microbial families, including Lachnospiraceae and Ruminococcaceae, are predictive of treatment responses. We identified significant changes in abundance levels of specific bacterial genera in response to treatment, confirming the robustness of ISNs in capturing both linear and non-linear microbiota signals. Utilising network topological metrics, we further validated these findings, demonstrating that critical microbial features identified through ISNs can differentiate responders from non-responders with respect to various therapeutic outcomes. The study highlights the potential of ISNs to provide individualised insights into microbiota-driven therapeutic responses, emphasising the need for larger cohort studies to enhance the accuracy of molecular biomarkers. This innovative methodology paves the way for more personalised and effective treatment strategies in managing IBD.</p>2025-01-29T05:19:52ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fmolb.2024.1490533.s003https://figshare.com/articles/dataset/Table_3_Individual-network_based_predictions_of_microbial_interaction_signatures_for_response_to_biological_therapies_in_IBD_patients_xlsx/28301414CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/283014142025-01-29T05:19:52Z |
| spellingShingle | Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsx Federico Melograna (12202905) Molecular Biology inflammatory bowel disease therapy fecal microbiota 16S profiling individual specific networks response prediction |
| status_str | publishedVersion |
| title | Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsx |
| title_full | Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsx |
| title_fullStr | Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsx |
| title_full_unstemmed | Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsx |
| title_short | Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsx |
| title_sort | Table 3_Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients.xlsx |
| topic | Molecular Biology inflammatory bowel disease therapy fecal microbiota 16S profiling individual specific networks response prediction |